Dr. Petr F. Hausner
Dr. Petr Hausner is a medical oncologist at the University of Maryland Greenebaum Cancer Center in Baltimore, Maryland and associate professor of medicine at the university’s medical school. He specializes in the treatment of several types of cancer: mesothelioma and other malignancies of the lungs; melanoma, Kaposi sarcoma and other skin cancers; esophageal cancer, and other specialties.
Dr. Hausner studied in Czechoslovakia, receiving his medical degree from Charles University in Prague. After completing a residency at the same university, he came to the United States to complete a fellowship in oncology at the National Institutes of Health. He is board certified in internal medicine and oncology.
While treating patients is Dr. Hausner’s main focus, he is also involved in research, an important part of working at a teaching university. With more than 100 clinical trials ongoing at the Greenebaum Cancer Center, Dr. Hausner has the opportunity to pursue new modes of inquiry about cancer in pursuit of a cure. This can also be a benefit to patients at Greenebaum, who have access not only to standard methods of treatment like chemotherapy and surgery, but also to experimental drugs and brand new treatment options.
Because the University of Maryland is among the top 25 rated cancer centers in the United States, Dr. Hausner’s office is often a beacon of hope for patients who have been unsuccessful in their treatments elsewhere. An experienced staff allows Dr. Hausner’s office to treat these patients successfully, he says. “We take care of not only patients with newly diagnosed cancer, but very often advanced cancer, patients who failed other treatments in other institutions,” he says. “I think we can do that, because we have a fantastic team.”
In his laboratory, Dr. Hausner studies intercellular communications and the process by which mesothelioma cells spread — a hugely important task if researchers hope to understand and eventually eradicate the disease. And in addition to his work at the University of Maryland, Dr. Hausner also serves as Chief of Hemotology and Oncology at the Baltimore VA Medical Center.
Hausner P, Venzon DJ, Grogan W, Kirsch I: The "Comparative Growth Assay“: Examining the Interplay of Anti-cancer Agents with Cells Carrying Single Gene Alterations. Neoplasia, 1(4):356-67, 1999.
Kwong KF, Edelman MJ, Suntharalingam M, Cooper LB, Gamliel Z, Burrows W, Hausner P, Doyle LA, Krasna MJ. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg, 129(6):1250-7, 2005.
Edelman, MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor M, Bisaccia S: Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell-lung cancer. J Clin Oncol, 23(24):5774-8, 2005.
Tummala, MK, Hausner, PF., McGuire, WP, Gipson, T, Berkman A: Testis: A sanctuary site in Merkel cell carcinoma. J Clin Oncol, 24(6):1008-9, 2006.
Hassan, R, Alexander, R. Antman, K, Boffetta, P, Churg,A, Coit, D, Hausner, P, Kennedy, R, Kindler, H, Metintas, M, Mutti, L, Onda, M., Pass, H, Premkumar, A, Toggli, V, Sterman, D., Sugarbaker, P, Taub, R, Verschraegen.: Current Treatment Options and Biology of Peritoneal Mesothelioma: Meeting Summary of the First NIH Peritoneal Mesothelioma Conference, Annals of Oncology, 2006, in press.Sources
University of Maryland School of Medicine — Dr. Petr Hausner
University of Maryland Directory Listing — Dr. Petr Hauser